Hero

Press & Media

svg+xml;charset=utf
Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitorsPress Release

Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors

March 26, 2026 Read More
svg+xml;charset=utf
Excellergy Presents New Data at 2026 AAAAI Annual Meeting Demonstrating Rapid and Sustained Allergic Effector Cell Control and Announces First Subjects Dosed in Phase 1 DISARM TrialPress Release

Excellergy Presents New Data at 2026 AAAAI Annual Meeting Demonstrating Rapid and Sustained Allergic Effector Cell Control and Announces First Subjects Dosed in Phase 1 DISARM Trial

February 27, 2026 Read More
svg+xml;charset=utf
Excellergy Debuts with $70 Million Series A Financing to Advance First-in-Class Portfolio of Trifunctional Effector Cell Response Inhibitors (ECRIs) for Complete Allergic ControlPress Release

Excellergy Debuts with $70 Million Series A Financing to Advance First-in-Class Portfolio of Trifunctional Effector Cell Response Inhibitors (ECRIs) for Complete Allergic Control

October 13, 2025 Read More